Targeted anti-cancer therapy in the elderly

Critical Reviews in Oncology/Hematology

Volumn 78, Issue 3, 2011, Pages 227-242

  Gonsalves, Wilson ^a   Ganti, Apar Kishor ^b,c  

^a CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

^b VA NEBRASKA WESTERN IOWA HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Elderly; Monoclonal antibodies; Small molecule inhibitors; Targeted therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; BORTEZOMIB; CAPECITABINE; CETUXIMAB; DASATINIB; DEXAMETHASONE; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IBRITUMOMAB TIUXETAN; IMATINIB; INTERFERON; IRINOTECAN; LAPATINIB; LENALIDOMIDE; MELPHALAN; OXALIPLATIN; PANITUMUMAB; PLACEBO; PREDNISOLONE; RITUXIMAB; SORAFENIB; SUNITINIB; THALIDOMIDE; TOSITUMOMAB; TRASTUZUMAB;

ACNE; ACUTE LYMPHOCYTIC LEUKEMIA; ANOREXIA; APPLICATION SITE REACTION; ARTERY THROMBOSIS; ASTHENIA; BLEEDING; BLOOD TOXICITY; BONE DISEASE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER THERAPY; CARDIOTOXICITY; CHRONIC MYELOID LEUKEMIA; COLON CANCER; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DEHYDRATION; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DIZZINESS; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDEMA; FATIGUE; FEBRILE NEUTROPENIA; GASTROINTESTINAL STROMAL TUMOR; GASTROINTESTINAL SYMPTOM; GLIOBLASTOMA; HEAD AND NECK CANCER; HEADACHE; HUMAN; HYPERTENSION; INFECTION; INTERMETHOD COMPARISON; KIDNEY CARCINOMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG NON SMALL CELL CANCER; MANTLE CELL LYMPHOMA; MENTAL DISEASE; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NAIL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; RASH; REVIEW; SKIN TOXICITY; SOMNOLENCE; STOMATITIS; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT OUTCOME; WOUND HEALING IMPAIRMENT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; QUALITY OF LIFE;

EID: 79955660925     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2010.06.001     Document Type: Review

References (100)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 2008, 58:71-96.
2. Sawhney R., Sehl M., Naeim A. Physiologic aspects of aging: impact on cancer management and decision making, part I. Cancer J 2005, 11:449-460.
3. Oshita F., Kurata T., Kasai T., et al. Prospective evaluation of the feasibility of cisplatin-based chemotherapy for elderly lung cancer patients with normal organ functions. Jpn J Cancer Res 1995, 86:1198-1202.
4. Egorin M.J. Cancer pharmacology in the elderly. Semin Oncol 1993, 20:43-49.
5. Hardy S.E., Studenski S.A. Fatigue and function over 3 years among older adults. J Gerontol A: Biol Sci Med Sci 2008, 63:1389-1392.
6. Luciani A., Jacobsen P.B., Extermann M., et al. Fatigue and functional dependence in older cancer patients. Am J Clin Oncol 2008, 31:424-430.
7. Tsuruo T., Naito M., Tomida A., et al. Molecular targeting therapy of cancer: drug resistance, apoptosis and survival signal. Cancer Sci 2003, 94:15-21.
8. Weiner L.M., Dhodapkar M.V., Ferrone S. Monoclonal antibodies for cancer immunotherapy. Lancet 2009, 373:1033-1040.
9. Zhang J., Yang P.L., Gray N.S. Targeting cancer with small molecule kinase inhibitors. Nat Rev Cancer 2009, 9:28-39.
10. Herbst R.S. Erlotinib (Tarceva): an update on the clinical trial program. Semin Oncol 2003, 30:34-46.
11. Shepherd F.A., Rodrigues Pereira J., Ciuleanu T., et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005, 353:123-132.
12. Wheatley-Price P., Ding K., Seymour L., Clark G.M., Shepherd F.A. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2008, 26:2350-2357.
13. Jackman D.M., Yeap B.Y., Lindeman N.I., et al. Phase II clinical trial of chemotherapy-naive patients > or =70 years of age treated with erlotinib for advanced non-small-cell lung cancer. J Clin Oncol 2007, 25:760-766.
14. Tsao M.S., Sakurada A., Cutz J.C., et al. Erlotinib in lung cancer-molecular and clinical predictors of outcome. N Engl J Med 2005, 353:133-144.
15. Pao W., Wang T.Y., Riely G.J., et al. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2005, 2:e17.
16. Carlson J., Oestreicher N., Lubeck D.P., Ramsey S.D., Veenstra D.L. Cost-effectiveness of erlotinib vs. docetaxel or pemetrexed in the treatment of refractory non-small cell lung cancer (NSCLC). J Clin Oncol 2007, 25:7664. [Meeting Abstracts].
17. Moore M.J., Goldstein D., Hamm J., et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007, 25:1960-1966.
18. Miksad R.A., Schnipper L., Goldstein M. Does a statistically significant survival benefit of erlotinib plus gemcitabine for advanced pancreatic cancer translate into clinical significance and value?. J Clin Oncol 2007, 25:4506-4507. [author reply 4508].
19. Radulovic S., Bjelogrlic S.K. Sunitinib, sorafenib and mTOR inhibitors in renal cancer. J BUON 2007, 12(Suppl. 1):S151-S162.
20. Escudier B., Eisen T., Stadler W.M., et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007, 356:125-134.
21. Eisen T., Oudard S., Szczylik C., et al. Sorafenib for older patients with renal cell carcinoma: subset analysis from a randomized trial. J Natl Cancer Inst 2008, 100:1454-1463.
22. Bukowski R.M., Stadler W.M., Figlin R.A., et al. Advanced Renal Cell Carcinoma Sorafenib Expanded Access Program in North America: safety and efficacy of sorafenib in elderly patients (pts) >=65 years: a subset analysis from the Advanced Renal Cell Carcinoma Sorafenib (ARCCS) Expanded Access Program in North America. J Clin Oncol 2008, 26:5045. [Meeting Abstracts].
23. Gao X., Reddy P., Dhanda R., et al. Cost-effectiveness of sorafenib versus best supportive care in advanced renal cell carcinoma. J Clin Oncol 2006, 24:4604. [Meeting Abstracts].
24. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008, 359:378-390.
25. Cheng A.L., Kang Y.K., Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009, 10:25-34.
26. Vitale A., Volk M.L., Pastorelli D., et al. Use of sorafenib in patients with hepatocellular carcinoma before liver transplantation: a cost-benefit analysis while awaiting data on sorafenib safety. Hepatology 2010, 51:165-173.
27. Heng D.Y., Bukowski R.M. Anti-angiogenic targets in the treatment of advanced renal cell carcinoma. Curr Cancer Drug Targets 2008, 8:676-682.
28. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
29. Figlin R.A., Hutson T.E., Tomczak P., et al. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008, 26:5024. [Meeting Abstracts].
30. Gore M.E., Porta C., Oudard S., et al. Sunitinib in metastatic renal cell carcinoma (mRCC): preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol 2007, 25:5010. [Meeting Abstracts].
31. Remak E., Mullins C.D., Akobundu E., Charbonneau C., Woodruff K. Economic evaluations of sunitinib versus interferon-alfa (IFN-{alpha}) in first-line metastatic renal cell carcinoma (mRCC). J Clin Oncol 2007, 25:6607. [Meeting Abstracts].
32. Paz-Ares L., Garcia del Muro X., Grande E., Gonzalez P., Brosa M., Diaz S. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib. Clin Transl Oncol 2008, 10:831-839.
33. Frenel J.S., Bourbouloux E., Berton-Rigaud D., Sadot-Lebouvier S., Zanetti A., Campone M. Lapatinib in metastatic breast cancer. Womens Health (Lond Engl) 2009, 5:603-612.
34. Geyer C.E., Forster J., Lindquist D., et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
35. Le Q.A., Hay J.W. Cost-effectiveness analysis of lapatinib in HER-2-positive advanced breast cancer. Cancer 2009, 115:489-498.
36. Rousselot P., Nicolini F., Mahon F.X., et al. High efficacy and particular safety profile of imatinib mesylate (Glivec(R)) in elderly patients with CML in chronic phase: results of the AFR04 prospective study. ASH Annual Meeting Abstracts, vol. 110 2007, 1039.
37. Ata R.L., Breccia M., Sica S., et al. Treatment with imatinib in very elderly (>75 years) CML patients. ASH Annual Meeting Abstracts, vol. 112 2008, 1096.
38. Bassi S., Castagnetti F., Amabile M., et al. Imatinib in the treatment of CML patients >=65 years old in late chronic phase: results of a phase II study of the GIMEMA CML working party. ASH Annual Meeting Abstracts, vol. 104 2004, 2935.
39. Reed S.D., Anstrom K.J., Li Y., Schulman K.A. Updated estimates of survival and cost effectiveness for imatinib versus interferon-alpha plus low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukaemia. Pharmacoeconomics 2008, 26:435-446.
40. Mabasa V.H., Taylor S.C., Chu C.C., et al. Verification of imatinib cost-effectiveness in advanced gastrointestinal stromal tumor in British Columbia (VINCE-BC study). J Oncol Pharm Pract 2008, 14:105-112.
41. Keam S.J. Dasatinib: in chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia. BioDrugs 2008, 22:59-69.
42. Iuliano F., Russo A., Caroleo M.C., Conforti F., Serra A. Escalated dasatinib dose up to 60mg O.D. in elderly patients with chronic myeloid leukemia in late chronic phase resistant to or intolerant of imatinib-12 months follow-up. ASH Annual Meeting Abstracts, vol. 112 2008, 4283.
43. Minda K., Taylor M.J., Cerri K.H., Davis C., Kan H.J., Ray S. An economic evaluation of dasatinib as a treatment for chronic phase chronic myeloid leukaemia in Scotland. Value Health 2007, 10:14887.
44. Sandler A. Bevacizumab in non small cell lung cancer. Clin Cancer Res 2007, 13:s4613-s4616.
45. Sandler A., Gray R., Perry M.C., et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006, 355:2542-2550.
46. Ramalingam S.S., Dahlberg S.E., Langer C.J., et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol 2008, 26:60-65.
47. Grusenmeyer P.A., Gralla R.J. Examining the cost and cost-effectiveness of adding bevacizumab to carboplatin and paclitaxel in advanced non-small cell lung cancer. J Clin Oncol 2006, 24:6057. [Meeting Abstracts].
48. Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
49. Kabbinavar F.F., Schulz J., McCleod M., et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005, 23:3697-3705.
50. Kozloff M.F., Sugrue M.M., Purdie D.M., et al. Safety and effectiveness of bevacizumab (BV) and chemotherapy (CT) in elderly patients (pts) with metastatic colorectal cancer (mCRC): results from the BRiTE observational cohort study. J Clin Oncol 2008, 26:4026. [Meeting Abstracts].
51. Raman A.K., Lombardo J.C., Chandrasekhar R., Fakih M.G. Bevacizumab (BV) related adverse events among various age groups of elderly patients with advanced colorectal cancer. J Clin Oncol 2007, 25:14546. [Meeting Abstracts].
52. Tappenden P., Jones R., Paisley S., Carroll C. Systematic review and economic evaluation of bevacizumab and cetuximab for the treatment of metastatic colorectal cancer. Health Technol Assess 2007, 11:1-128. iii-iv.
53. Miller K., Wang M., Gralow J., et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007, 357:2666-2676.
54. Dedes K.J., Matter-Walstra K., Schwenkglenks M., et al. Bevacizumab in combination with paclitaxel for HER-2 negative metastatic breast cancer: an economic evaluation. Eur J Cancer 2009, 45:1397-1406.
55. Bajetta E., Ravaud A., Bracarda S., et al. Efficacy and safety of first-line bevacizumab (BEV) plus interferon-{alpha}2a (IFN) in patients (pts) >=65 years with metastatic renal cell carcinoma (mRCC). J Clin Oncol 2008, 26:5095. [Meeting Abstracts].
56. Nghiemphu P.L., Liu W., Lee Y., et al. Bevacizumab and chemotherapy for recurrent glioblastoma: a single-institution experience. Neurology 2009, 72:1217-1222.
57. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
58. Wong S.F. Cetuximab: an epidermal growth factor receptor monoclonal antibody for the treatment of colorectal cancer. Clin Ther 2005, 27:684-694.
59. Cunningham D., Humblet Y., Siena S., et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004, 351:337-345.
60. Bouchahda M., Macarulla T., Spano J.P., et al. Cetuximab and irinotecan-based chemotherapy as an active and safe treatment option for elderly patients with extensively pre-treated metastatic colorectal cancer. J Clin Oncol 2007, 25:14528. [Meeting Abstracts].
61. Sastre J., Aranda E., Gravalos C., et al. Single-agent cetuximab as first-line treatment for elderly patients with advanced colorectal cancer. Preliminary results of a TTD phase II study. Ann Oncol 2006, 17(Suppl. 9):ix114.
62. Lievre A., Bachet J.B., Le Corre D., et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006, 66:3992-3995.
63. Rivera F., Gravalos C., Massutí B., et al. 4004 cetuximab plus capecitabine as first-line treatment for elderly patients (pts) with advanced colorectal cancer (mCRC). Final analysis of activity and survival according to KRAS status-the TTD-06-01 Spanish Cooperative Group trial. Eur J Cancer Suppl 2009, 7:216-1216.
64. Mittmann N., Au H.J., Tu D., et al. Prospective cost-effectiveness analysis of cetuximab in metastatic colorectal cancer: evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 trial. J Natl Cancer Inst 2009, 101:1182-1192.
65. Vermorken J.B., Mesia R., Rivera F., et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 2008, 359:1116-1127.
66. Sambrook J., Levy A.R., Johnston K.M., et al. Cost-effectiveness of cetuximab for the first-line treatment of squamous cell carcinoma of the head and neck (SCCHN) in Canada. J Clin Oncol 2009, 27:e17000. [Meeting Abstracts].
67. Van Cutsem E., Peeters M., Siena S., et al. A phase III randomized controlled trial of panitumumab (Pmab) in patients (pts) with metastatic colorectal cancer (mCRC): subset analyses in elderly pts and in pts with poor performance status. Proc Gastrointestinal Cancers Symposium 2007, 349.
68. Peeters M., Price T., Hotko Y., et al. 14LBA randomized phase 3 study of panitumumab with FOLFIRI vs FOLFIRI alone as second-line treatment (tx) in patients (pts) with metastatic colorectal cancer (mCRC). Eur J Cancer Suppl 2009, 7:10.
69. Douillard J., Siena S., Cassidy J., et al. 10LBA randomized phase 3 study of panitumumab with FOLFOX4 compared to FOLFOX4 alone as 1st-line treatment (tx) for metastatic colorectal cancer (mCRC): the PRIME trial. Eur J Cancer Suppl 2009, 7:6-16.
70. Graham C.N., Borker R., Oppe M., et al. Cost-effectiveness of panitumumab plus best supportive care (BSC) compared with BSC alone in chemorefractory metastatic colorectal cancer patients with wild-type KRAS tumor status in Netherlands. Ann Oncol 2009, 19:134.
71. Valabrega G., Montemurro F., Aglietta M. Trastuzumab: mechanism of action, resistance and future perspectives in HER2-overexpressing breast cancer. Ann Oncol 2007, 18:977-984.
72. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
73. Romond E.H., Perez E.A., Bryant J., et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
74. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
75. Tan-Chiu E., Yothers G., Romond E., et al. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
76. Giuliani R., Minisini A.M., Paesmans M., et al. Is age a risk factor of congestive heart failure (CHF) in patients receiving trastuzumab (H)? Results from two Belgian compassionate use programs in metastatic breast cancer (MBC) patients (pts). J Clin Oncol 2004, 22:838. [Meeting Abstracts].
77. Brunello A., Monfardini S., Crivellari D., et al. Multicenter analysis of activity and safety of trastuzumab plus chemotherapy in advanced breast cancer in elderly women (>=70 years). J Clin Oncol 2008, 26:1096. [Meeting Abstracts].
78. Fyfe G.A., Mass R., Murphy M., Slamon D.J. Survival benefit of traztuzumab (herceptin) and chemotherapy in older (age>60) patients. Proc Am Soc Clin Oncol 2001, 20. [Abstr. 189].
79. Liberato N.L., Marchetti M., Barosi G. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2007, 25:625-633.
80. Nadler L.M., Stashenko P., Hardy R., et al. Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen. Cancer Res 1980, 40:3147-3154.
81. Feugier P., Van Hoof A., Sebban C., et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23:4117-4126.
82. Habermann T.M., Weller E.A., Morrison V.A., et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006, 24:3121-3127.
83. Groot M.T., Lugtenburg P.J., Hornberger J., Huijgens P.C., Uyl-de Groot C.A. Cost-effectiveness of rituximab (MabThera) in diffuse large B-cell lymphoma in The Netherlands. Eur J Haematol 2005, 74:194-202.
84. Emmanouilides C., Witzig T.E., Wiseman G.A., et al. Safety and efficacy of yttrium-90 ibritumomab tiuxetan in older patients with non-Hodgkin's lymphoma. Cancer Biother Radiopharm 2007, 22:684-691.
85. 90Y-Zevalin) versus rituximab monotherapy in patients with relapsed follicular lymphoma. ASH Annual Meeting Abstracts, vol. 106 2005, 2436.
86. Gregory S.A., Zelenetz A., Knox S.J., Vose J., Leonard J.P., Kaminski M. Tositumomab and iodine I 131 tositumomab (the BEXXAR(R) therapeutic regimen) shows efficacy in elderly patients (pts) with relapsed/refractory low-grade (LG), follicular, and transformed non-Hodgkin's lymphoma (NHL). ASH Annual Meeting Abstracts, vol. 104 2004, 2630.
87. Flowers C.R., Sambrook J.C., Briggs A., Osenenko K., Wang H., Dalal M.R. Cost-effectiveness of tositumomab and iodine I-131 tositumomab (Bexxar therapeutic regimen (BTR)), in treatment of non-Hodgkin lymphoma (NHL). J Clin Oncol 2007, 25:8089. [Meeting Abstracts].
88. Mateos M.V., Hernandez J.M., Hernandez M.T., et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood 2006, 108:2165-2172.
89. Richardson P.G., Sonneveld P., Schuster M.W., et al. Safety and efficacy of bortezomib in high-risk and elderly patients with relapsed multiple myeloma. Br J Haematol 2007, 137:429-435.
90. Bagust A., Haycox A.R., Boland A., et al. Economic evaluation of bortezomib (VELCADE) for relapsed and refractory multiple myeloma. ASH Annual Meeting Abstracts, vol. 104 2004, 268.
91. Kane R.C., Dagher R., Farrell A., et al. Bortezomib for the treatment of mantle cell lymphoma. Clin Cancer Res 2007, 13:5291-5294.
92. Ludwig H., Hajek R., Tothova E., et al. Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma. Blood 2009, 113:3435-3442.
93. Rajkumar S.V., Blood E., Vesole D., Fonseca R., Greipp P.R. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol 2006, 24:431-436.
94. Palumbo A., Bringhen S., Caravita T., et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet 2006, 367:825-831.
95. Facon T., Mary J.Y., Hulin C., et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet 2007, 370:1209-1218.
96. List A.F. Lenalidomide: from bench to bedside (part 1). Cancer Control 2006, 13(Suppl.):2-3.
97. Reece D.E., Masih-Khan E., Chen C., et al. Lenalidomide (Revlimid(R)) +/- corticosteroids in elderly patients with relapsed/refractory multiple myeloma. ASH Annual Meeting Abstracts, vol. 108 2006, 3550.
98. Chanan-Khan A., Dimopoulos M.A., Weber D.M., et al. Safety and efficacy outcomes with lenalidomide plus dexamethasone in relapsed or refractory multiple myeloma were not significantly different for the treatment of patients with or without high-risk disease or elderly status. ASH Annual Meeting Abstracts, vol. 112 2008, 3701.
99. Ritchie E., Lachs M. Management of myelodysplastic syndromes in the geriatric patient. Curr Hematol Malign Rep 2009, 4:3-9.
100. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.